Alector, Inc.
NASDAQ:ALEC
Overview | Financials
Company Name | Alector, Inc. |
Symbol | ALEC |
Currency | USD |
Price | 1.82 |
Market Cap | 178,237,332 |
Dividend Yield | 0% |
52-week-range | 1.725 - 8.9 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Arnon Rosenthal Ph.D. |
Website | https://www.alector.com |
An error occurred while fetching data.
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD